Previous and active tuberculosis in COVID-19 patients increases risk of death and prolongs recovery

Karla Therese L. Sy[1,2*]; Nel Jason L. Haw[3±]; Jhanna Uy[3,4±]

[1] Department of Epidemiology, Boston University School of Public Health, Boston MA, United States

[2] Department of Global Health, Boston University School of Public Health, Boston MA, United States

[3] Health Sciences Program, School of Science and Engineering, Ateneo de Manila University, Manila, Philippines

[4] Philippine Institute for Development Studies, Manila, Philippines

[±] Authors contributed equally

*Correspondence should be addressed to: Karla Therese L. Sy at rsy@bu.edu, 715 Albany Street, Boston MA, 02118, USA

Keywords: COVID-19; SARS-CoV-2; Tuberculosis; Philippines

Abstract

Background: There is growing literature on the association of SARS-CoV-2 and other chronic respiratory conditions, such as COPD and asthma. However, little is known about the relationship between coinfection with tuberculosis (TB) and COVID-19. We aimed to compare the risk and survival time of death and recovery among COVID-19 patients with and without TB.

Methods: We created a 4:1 propensity score matched sample of COVID-19 patients without and with TB, using SARS-CoV-2 surveillance data in the Philippines. We conducted a longitudinal cohort analysis of matched COVID-19 patients as of May 17, 2020, following them until June 15, 2020. The primary analysis estimated the risk ratios of death and recovery comparing COVID-19 patients with and without TB. Kaplan-Meier curves described time-to-death and time-to-recovery stratified by TB status, and differences in survival were assessed using the Wilcoxon test. We also conducted the same analysis on a subsample of admitted COVID-19 patients only.

Results: The risk of death in COVID-19 patients with TB was 2.17 times greater compared to those without TB (95% CI: 1.40-3.37). The risk of recovery in TB patients was 25% less than the risk among those without TB (RR=0.75, 0.63-0.91). Similarly, time-to-death among COVID-19 patients with TB was significantly shorter (p=0.0031) and time-to-recovery in TB patients was significantly longer than patients without TB (p=0.0046).

Among those admitted, COVID-19 TB patients also had a similar significant increase in risk of death (RR=2.25, 95% CI: 1.35-3.75); however, the risk of recovery was not significantly less (RR=0.84, 95% CI: 0.68-1.06). Time-to-death among those with TB was also significantly longer (p=0.0031) than those without TB, but there was no difference in time-to-recovery (p=0.17).

Conclusions: Our findings show that coinfection with tuberculosis increases morbidity and mortality in COVID-19 patients. Our findings reiterate the need to prioritize routine and testing services for tuberculosis, even with increased disruptions to health systems during the SARS-CoV-2 pandemic. Additional research needs to focus on the interrelationship between TB and COVID-19 for appropriate planning and resource allocation, as SARS-CoV-2 continues to spread worldwide.

Introduction

As of July 2020, the global burden of the COVID-19 pandemic has reached 8 million cases, and has caused large-scale outbreaks in many countries (1). The COVID-19 pandemic has caused substantial strain to healthcare systems worldwide, particularly in resource-limited settings with high prevalence of comorbid conditions such as TB. TB is also major global cause of morbidity and mortality, and was the cause of 1.4 million deaths in 2018, the largest single contribution by any one infectious disease (2). TB disproportionately affects low-and-middle income countries (LMICs), where TB epidemics are fueled by coinfection with HIV/AIDS (3) and multidrug resistance (4, 5). There have been significant TB treatment and program disruptions due to the pandemic (6, 7), which have disproportionate impacts on socially disadvantaged communities with TB (8). In particular, there has been decreases in care seeking for TB treatment, lessened enrollment in TB research studies, interruptions in availability of TB medicine and other products, and issues with obtaining food and nutritional support during the pandemic (9).

The COVID-19 outbreak in the Philippines is a continuing public health crisis, with 12,513 reported cases as of May 17, 2020. TB is also a major public health problem in the Philippines as it has the third highest prevalence of TB globally, with one million individuals with active TB disease (10). Most research on the SARS-CoV-2 pathogen have been conducted in high-income countries, and studies suggest worse outcomes among COVID-19 patients with other respiratory diseases in these countries, such as COPD (11, 12) and asthma (13). However, little is known about the relationship between coinfection with tuberculosis (TB) and COVID-19 outcomes. Pulmonary TB involves active destruction of lung parenchyma (14), which may predispose COVID-19 patients with TB to more aggravated disease and greater mortality. We hypothesize that COVID-19 patients with previous or active TB may have more severe clinical outcomes than those without TB. This study compares the risk of and time-to-death and

recovery among COVID-19 patients who have and do not have TB coinfection in the Philippines.

Materials and Methods

Data

Data were obtained from the Philippine national COVID-19 surveillance managed and implemented by the Philippine Department of Health Epidemiology Bureau (DOH-EB). One of the authors (NH) is involved in COVID-19 surveillance as a consultant. Data on Philippine COVID-19 cases have been de-identified and most of the data are publicly available through the DOH DataDrop initiative (https://www.doh.gov.ph/covid19tracker), thus institutional review board approval was deemed unnecessary.

Study Population

We included all reported COVID-19 cases in the Philippines as of May 17, 2020, following them until June 15, 2020. COVID-19 cases were confirmed cases with positive real-time reverse transcription polymerase chain reaction (RT-PCR) from laboratories accredited by the DOH and Research Institute for Tropical Medicine (RITM) (15). Information on confirmed cases were collected using structured interviews upon initial consultation by the physician or nurse on duty as part of routine surveillance using a case investigation form (CIF), filled out manually or electronically. We used propensity score matching to create similar populations of COVID-19 patients with and without previous and active TB. To create the propensity scores, we predicted the risk of having TB using logistic regression with the potential confounders age, sex, and other comorbid conditions (chronic pulmonary obstructive disorder (COPD), asthma, diabetes, hypertension, diabetes, cancer, renal disease, cardiac disease, and autoimmune disorders). We matched 1 COVID-19 patient with TB to 4 without TB, using nearest neighbor matching of propensity scores, a caliper of 0.05, and with no replacement. As a secondary analysis, we

created a propensity score matched subsample of only admitted COVID-19 patients, and conducted the same analysis.

Exposure

Our main exposure of interest was a history or current diagnosis of TB. Comorbidity data and death certificate data encoded as part of the CIF were used as data sources to determine the history of TB infection.

Outcome

The two main outcomes of interest were (1) death and (2) recovery. We modelled this as a dichotomous (yes/no) variable, as well as a time-to-event variable. The time-to-event variables for both primary outcomes were the time from symptom onset to outcome (i.e., time from symptom onset to death, time from symptom onset to recovery). Death was defined as deaths happening during active COVID-19 infection and declared as a death by the DOH-EB. Recovery was defined as those who had been declared as recovered by the DOH-EB based on rapidly evolving surveillance criteria on testing, clinical improvement, and additional days of quarantine. We also assessed the time from hospital admission to discharge among those admitted to the hospital; hospitalization dates were validated from medical records. As a secondary outcome, we also assessed the relative risk of admission among the propensity score matched sample.

Statistical analyses

Descriptive statistics were generated to characterize the sample; t-tests were used to assess differences between age between those with and without TB. We conducted Pearson chi-square tests to examine differences in gender, comorbidities, health status and admission status. The primary analysis estimated the relative risks (risk ratios) of death and recovery with a modified Poisson regression with a robust variance estimator and a log link.

Kaplan-Meier curves were used to plot survival curves of the time-to-event variables stratified by TB status. We conducted nonparametric analysis for differences in survival in those with and without TB using the Wilcoxon test. Individuals were censored at their last date of follow-up if they did not have the outcome of interest. For the analysis of time-to-recovery, we censored those who had died on last day of administrative follow-up for the whole sample. This was done as to not upwardly the bias estimate of recovery by removing those who died as censored observations. All statistical analysis was conducted in R 4.0.0 (16).

Results

Propensity score matching

The initial unmatched sample had 12,513 COVID-19 patients, among which 113 (1.0%) had confirmed TB. Sex was significantly different between those with and without TB (p=0.001), as well as hypertension (p<0.001) and diabetes (p<0.006) (**Supplementary Table 1**). We removed all COVID-19 patients with missing covariates on variables included in the propensity score matching, including seven TB patients; 4,510 COVID-19 patients were used to create the final propensity-matched sample. The final analytical propensity-matched sample consisted of 530 COVID-19 patients, with 104 TB cases and 424 non-TB controls. Matching successfully created populations with similar observed baseline characteristics (all p>0.05; **Table 1**). The mean age of the sample was 48.9 (SD=18.88; 95% CI: 47.2-50.5), 68.9% male, 13.4% (n=71) died, while 67.7% (n=359) recovered. The unmatched sample of COVID-19 patients admitted to the hospital consisted of 3,869 people, where 70 (1.8%) were confirmed TB patients. In the propensity matched cohort of those admitted, three TB patients had missing covariates, and one TB patient did not have a control match; the final subsample included 66 TB patients and 264 matched controls with similar baseline characteristics (all p>0.05; **Table 1**).

Among those who tested positive with COVID-19, the risk of death among those with and without TB was significantly different; patients with TB had 2.17 times the risk of death relative to those without TB (95% CI: 1.40-3.37). When assessed only among those admitted, COVID-19 patients with TB also have a similar significant increase in risk of death (RR=2.25, 95% CI: 1.35-3.75). The risk of recovery among COVID-19 patients with TB was 25% less than the risk of recovery among those without TB (RR=0.75, 0.63-0.91). This finding was similar among those admitted; however, it was no longer significant (RR=0.84, 95% CI: 0.68-1.06). There was an increase of 20% in the risk of admission among those with TB (RR=1.20, 95% CI: 1.04-1.38) (**Table 2**).

Kaplan-Meier survival analysis demonstrated similar findings: the time-to-death among those with TB was significantly less than those without TB for both the propensity matched sample (p=0.0031) and in the subsample of those admitted (p=0.0052). Additionally, the time-to-recovery among COVID-19 patients with TB was significantly greater than those who did have TB (full sample p=0.0046; admitted only p=0.02) (**Figure 1**). However, the time-to-admission among those with and without TB were not significantly different (p=0.17).

Discussion

The ongoing SARS-CoV-2 pandemic poses a challenge for TB prevention and treatment worldwide. Our findings show COVID-19 patients with TB have a two-fold increased risk of death, and are less likely to recover. Moreover, they died faster and recovered more slowly than those without TB, contributing to substantial morbidity and mortality. Our findings are consistent with preliminary findings on the Western Cape province of South Africa, where a current diagnosis of TB increased risk of death by 2.5 times, and a previous diagnosis of TB increased risk of death by 50% (17). To our knowledge, this is the first longitudinal cohort study examining the associations between COVID-19 and TB in a high-burden TB setting. As COVID-19 cases

are continuing to increase in many low and middle income countries (LMICs) with high TB prevalence, such as Southern Africa, Latin America, and Asia (1), mitigation strategies need to target individuals with TB in order to reduce the burden of COVID-19 globally. Our results demonstrate the direct relationship of COVID-19 and TB, but SARS-CoV-2 also indirectly contributes additional TB-related morbidity and mortality. COVID-19 has and will continue to cause substantial strain to healthcare systems worldwide, and predictions expect increased mortality among TB patients due to significant TB program disruptions, diagnostic delays, TB treatment interruptions, and lack of access to drugs (6, 7, 9).

There are a number of limitations of the study. We utilized propensity score matching to adjust for sources of measured confounding; however, residual confounding could still be an issue on confounders we did not match on. Specifically, we did not have data on HIV/AIDs in our cohort, and this might have biased our estimates since those with TB are more likely to have HIV. However, propensity score matching on all other measured comorbid conditions would reduce confounding substantially, and any other potential residual confounding would be limited. Moreover, as this data was obtained from the Philippine national surveillance effort on COVID-19, there are some missing dates for the time-to-event outcomes. In survival analyses, we excluded individuals with missing dates, and conducted statistical tests to ensure that the confounder distribution of the included sample for each time-to-event analysis between those with and without TB were not significantly different (**Supplementary Table 2**) to ensure limited confounding. In addition, the main outcomes death and recovery could potentially have missing data due to loss-to-follow up; survival analysis accounted for the missing data by censoring on the last day of follow-up for patients without the outcome.

Our findings reiterate the need to continue prioritizing routine and testing services for TB, even with overarching increased disruption to health and social systems during this pandemic.

Moreover, since a large proportion of patients with TB are also coinfected with HIV, further research on the co-occurrence of these three epidemics, as well as other endemic communicable and noncommunicable diseases in high TB-burden countries, is imperative in order to accurately assess the burden of SARS-CoV-2 globally. Additional research needs to focus on the interrelationship between TB and COVID-19 for appropriate planning and resource allocation, as SARS-CoV-2 continues to spread worldwide.

Acknowledgements

Author contributions

K. Sy contributed to conceptualization. K. Sy, N. Haw, and J. Uy contributed to data acquisition. K. Sy contributed to data analysis. All authors contributed to interpretation of results and manuscript writing.

Funding details

This work was not supported by any funding sources.

Disclosure of interest

The authors have declared no conflicts of interest.

References

1. Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 Dashboard https://coronavirus.jhu.edu/map.html.
2. . World Health Organization (WHO) 2019 Global Tuberculosis Report.
3. Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011;24(2):351-76.
4. Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;92s:S15-s25.
5. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. Journal of applied microbiology. 2020;128(6):1547-67.
6. McQuaid CF, McCreesh N, Read JM, Sumner T, group Cnw, Houben RMGJ, et al. Contacts or care? Impact of COVID-19-related disruption on tuberculosis burden. Centre for Mathematical Modeling of Infectious Diseases Repository. 2020.
7. Maciel ELN, Gonçalves Júnior E, Dalcolmo MMP. Tuberculosis and coronavirus: what do we know? Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil. 2020;29(2):e2020128.
8. Stop TB Partnership, Imperial College, Avenir Health, Johns Hopkins University, and USAID. The potential impact of the COVID-19 response on tuberculosis in high-burden countries: a modelling analysis. 2020.
9. Stop TB Partnership. The TB Response is Heavily Impacted by the COVID-19 Pandemic 2020 [Available from: http://www.stoptb.org/news/stories/2020/ns20_014.html.

10. Gundo Aurel Weiler. World Health Organization. It's time to end TB in the Philippines. 2019 [Available from: https://www.who.int/philippines/news/commentaries/detail/it-s-time-to-end-tb-in-the-philippines#:~:text=Tuberculosis%20is%20an%20airborne%20disease,after%20South%20Africa%20and%20Lesotho.

11. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. Journal of medical virology. 2020.

12. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. The European respiratory journal. 2020;55(5).

13. Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020:2020.05.06.20092999.

14. Brace PT, Tezera LB, Bielecka MK, Mellows T, Garay D, Tian S, et al. Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology. PLoS Pathog. 2017;13(6):e1006367-e.

15. Food and Drug Administration Philippines. List of Approved COVID-19 Test Kits for Commercial Use (as of 26 Mar 2020, 2:00 PM). 2020.

16. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria2017

17. Western Cape: COVID-19 and HIV / Tuberculosis 2020 [Available from: https://storage.googleapis.com/stateless-bhekisisa-website/wordpress-uploads/2020/06/94d3ea42-covid_update_bhekisisa_wc_3.pdf.

Tables and Figures

Table 1. Demographic and health status of the propensity-scored matched full sample and matched admitted sample by TB status

Matched sample	Overall (n=530)	No TB (n=424)	TB (n=106)	*P*
Age (mean (SD))	48.86 (18.88)	48.84 (18.71)	48.92 (19.63)	0.968
Male (%)	373 (70.4)	300 (70.8)	73 (68.9)	0.794
Comorbidities (%)				
Hypertension	109 (20.6)	87 (20.5)	22 (20.8)	1.000
Diabetes	67 (12.6)	53 (12.5)	14 (13.2)	0.974
Cancer	6 (1.1)	5 (1.2)	1 (0.9)	1.000
Renal Cancer	16 (3.0)	12 (2.8)	4 (3.8)	0.849
Cardiac disease	41 (7.7)	33 (7.8)	8 (7.5)	1.000
Asthma	21 (4.0)	17 (4.0)	4 (3.8)	1.000
COPD	6 (1.1)	3 (0.7)	3 (2.8)	0.182
Autoimmune disease	0 (0)	0 (0)	0 (0)	1.000
Health Status (%)				
Died	71 (13.4)	46 (10.8)	25 (23.6)	0.001
Recovered	359 (67.7)	302 (71.2)	57 (53.8)	0.001
Admission Status (%)				0.038
Admitted	303 (57.2)	236 (55.7)	67 (63.2)	
Not Admitted	162 (30.6)	140 (33.0)	22 (20.8)	
Unknown	65 (12.3)	48 (11.3)	17 (16.0)	
Admitted sample	**Overall (n=330)**	**No TB (n=264)**	**TB (n=66)**	***P***
Age (mean (SD))	49.50 (18.54)	49.29 (17.71)	50.33 (21.68)	0.683
Male (%)	235 (71.2)	187 (70.8)	48 (72.7)	0.879
Comorbidities (%)				
Hypertension	80 (24.2)	64 (24.2)	16 (24.2)	1.000
Diabetes	51 (15.5)	41 (15.5)	10 (15.2)	1.000
Cancer	3 (0.9)	2 (0.8)	1 (1.5)	1.000
Renal Cancer	13 (3.9)	9 (3.4)	4 (6.1)	0.524
Cardiac disease	27 (8.2)	20 (7.6)	7 (10.6)	0.581
Asthma	1 (0.3)	0 (0.0)	1 (1.5)	0.453
COPD	1 (0.3)	0 (0.0)	1 (1.5)	0.453
Autoimmune disease	0 (0)	0 (0)	0 (0)	1.000
Health Status (%)				
Died	50 (15.2)	32 (12.1)	18 (27.3)	0.004
Recovered	218 (66.1)	180 (68.2)	38 (57.6)	0.138

Table 2. Risk ratios of death, recovery and admission among full matched sample and matched admitted sample

	RR (95% CI)	*P*
Matched cohort (n=530)		
Death	2.17 (1.4-3.37)	0.001
Recovery	0.75 (0.63-0.91)	0.003
Admission	1.20 (1.04-1.38)	0.012
Admitted only (n=330)		
Death	2.25 (1.35-3.75)	0.002
Recovery	0.84 (0.68-1.06)	0.137



Figure 1. Survival analysis for (a) time to death in whole matched sample (b) time to death in admitted subsample and (c) time to recovery in whole matched sample (d) time to recovery in admitted subsample

Supplementary Material

Supplementary Table 1. Demographic and health status of the unmatched full sample and unmatched admitted sample

Full sample	Overall (n=12,513)	No TB (n=4407)	TB (n=113)	*P*
Age (mean (SD))	44.21 (18.18)	49.64 (17.76)	49.15 (19.62)	0.774
Male (%)	6792 (54.3)	2346 (53.2)	80 (70.8)	<0.001
Comorbidities (%)				
Hypertension	1601 (35.5)	1579 (35.8)	22 (20.8)	0.002
Diabetes	1137 (25.2)	1123 (25.5)	14 (13.2)	0.006
Cancer	89 (2.0)	88 (2.0)	1 (0.9)	0.676
Renal Cancer	219 (4.9)	215 (4.9)	4 (3.8)	0.768
Cardiac disease	285 (6.3)	277 (6.3)	8 (7.5)	0.745
Asthma	292 (6.5)	288 (6.5)	4 (3.8)	0.346
COPD	37 (0.8)	34 (0.8)	3 (2.8)	0.075
Autoimmune disease	9 (0.2)	9 (0.2)	0 (0.0)	1.000
Health Status (%)				
Died	980 (7.8)	546 (12.4)	32 (28.3)	<0.001
Recovered	5867 (46.9)	3110 (70.6)	57 (50.4)	<0.001
Admission Status (%)				0.001
Admitted	3869 (30.9)	2394 (54.3)	70 (61.9)	
Not Admitted	2656 (21.2)	1540 (34.9)	22 (19.5)	
Unknown	5988 (47.9)	473 (10.7)	21 (18.6)	
Admitted sample	**Overall (n=3869)**	**No TB (n=2394)**	**TB (n=70)**	***P***
Age (mean (SD))	50.47 (18.30)	52.75 (17.90)	50.37 (21.17)	0.275
Male (%)	2168 (56.0)	1344 (56.2)	51 (72.9)	0.008
Comorbidities (%)				
Hypertension	977 (39.7)	961 (40.1)	16 (23.9)	0.011
Diabetes	749 (30.4)	739 (30.9)	10 (14.9)	0.008
Cancer	67 (2.7)	66 (2.8)	1 (1.5)	0.805
Renal Cancer	159 (6.5)	155 (6.5)	4 (6.0)	1.000
Cardiac disease	210 (8.5)	203 (8.5)	7 (10.4)	0.729
Asthma	164 (6.7)	163 (6.8)	1 (1.5)	0.141
COPD	30 (1.2)	28 (1.2)	2 (3.0)	0.441
Autoimmune disease	6 (0.2)	6 (0.3)	0 (0.0)	1.000
Health Status (%)				
Died	601 (15.5)	401 (16.8)	22 (31.4)	0.002
Recovered	2639 (68.2)	1650 (69.0)	38 (54.3)	0.013

Supplementary Table 2. Confounder distribution of each time-to-event analysis

Time-to-death				
Matched sample	**Overall (n=432)**	**No TB (n=333)**	**TB (n=99)**	***P***
Age (mean (SD))	49.52 (18.82)	49.83 (18.53)	48.51 (19.82)	0.540
Male (%)	304 (70.4)	236 (70.9)	68 (68.7)	0.770
Comorbidities (%)				
Hypertension	93 (21.5)	73 (21.9)	20 (20.2)	0.821
Diabetes	59 (13.7)	46 (13.8)	13 (13.1)	0.994
Cancer	4 (0.9)	3 (0.9)	1 (1.0)	1.000
Renal Cancer	13 (3.0)	9 (2.7)	4 (4.0)	0.727
Cardiac disease	37 (8.6)	29 (8.7)	8 (8.1)	1.000
Asthma	21 (4.9)	17 (5.1)	4 (4.0)	0.868
COPD	6 (1.4)	3 (0.9)	3 (3.0)	0.271
Autoimmune disease	432 (100.0)	333 (100.0)	99 (100.0)	1.000
Admitted sample	**Overall (n=301)**	**No TB (n=235)**	**TB (n=66)**	***P***
Age (mean (SD))	49.79 (18.53)	49.64 (17.59)	50.33 (21.68)	0.789
Male (%)	218 (72.4)	170 (72.3)	48 (72.7)	1.000
Comorbidities (%)				
Hypertension	75 (24.9)	59 (25.1)	16 (24.2)	1.000
Diabetes	48 (15.9)	38 (16.2)	10 (15.2)	0.992
Cancer	3 (1.0)	2 (0.9)	1 (1.5)	1.000
Renal Cancer	12 (4.0)	8 (3.4)	4 (6.1)	0.536
Cardiac disease	24 (8.0)	17 (7.2)	7 (10.6)	0.524
Asthma	1 (0.3)	0 (0.0)	1 (1.5)	0.497
COPD	1 (0.3)	0 (0.0)	1 (1.5)	0.497
Autoimmune disease	301 (100.0)	235 (100.0)	66 (100.0)	1.000
Time-to-recovery				
Matched sample	**Overall (n=303)**	**No TB (n=231)**	**TB (n=72)**	***P***
Age (mean (SD))	50.49 (19.41)	51.07 (18.84)	48.62 (21.16)	0.352
Male (%)	215 (71.0)	167 (72.3)	48 (66.7)	0.441
Comorbidities (%)				
Hypertension	62 (20.5)	48 (20.8)	14 (19.4)	0.938
Diabetes	44 (14.5)	35 (15.2)	9 (12.5)	0.714
Cancer	3 (1.0)	2 (0.9)	1 (1.4)	1.000
Renal Cancer	12 (4.0)	8 (3.5)	4 (5.6)	0.654
Cardiac disease	33 (10.9)	25 (10.8)	8 (11.1)	1.000
Asthma	13 (4.3)	10 (4.3)	3 (4.2)	1.000
COPD	5 (1.7)	3 (1.3)	2 (2.8)	0.741

Autoimmune disease	303 (100.0)	231 (100.0)	72 (100.0)	1.000
Time-to-recovery				
Admitted sample	**Overall (n=216)**	**No TB (n=168)**	**TB (n=48)**	***P***
Age (mean (SD))	50.02 (19.25)	50.24 (18.01)	49.27 (23.27)	0.760
Male (%)	158 (73.1)	123 (73.2)	35 (72.9)	1.000
Comorbidities (%)				
Hypertension	59 (27.3)	49 (29.2)	10 (20.8)	0.338
Diabetes	37 (17.1)	31 (18.5)	6 (12.5)	0.454
Cancer	2 (0.9)	1 (0.6)	1 (2.1)	0.924
Renal Cancer	9 (4.2)	5 (3.0)	4 (8.3)	0.219
Cardiac disease	24 (11.1)	17 (10.1)	7 (14.6)	0.543
Asthma	1 (0.5)	0 (0.0)	1 (2.1)	0.503
COPD	1 (0.5)	0 (0.0)	1 (2.1)	0.503
Autoimmune disease	216 (100.0)	168 (100.0)	48 (100.0)	1.000
Time-to-admission				
Matched sample	**Overall (n=441)**	**No TB (n=341)**	**TB (n=100)**	***P***
Age (mean (SD))	49.90 (18.87)	50.26 (18.60)	48.68 (19.80)	0.463
Male (%)	311 (70.5)	243 (71.3)	68 (68.0)	0.614
Comorbidities (%)				
Hypertension	94 (21.3)	74 (21.7)	20 (20.0)	0.821
Diabetes	61 (13.8)	48 (14.1)	13 (13.0)	0.913
Cancer	4 (0.9)	3 (0.9)	1 (1.0)	1.000
Renal Cancer	14 (3.2)	10 (2.9)	4 (4.0)	0.833
Cardiac disease	40 (9.1)	32 (9.4)	8 (8.0)	0.821
Asthma	21 (4.8)	17 (5.0)	4 (4.0)	0.889
COPD	6 (1.4)	3 (0.9)	3 (3.0)	0.263
Autoimmune disease	441 (100.0)	341 (100.0)	100 (100.0)	1.000